Table 1. Characteristics of Patients and Disease According to Treatment Group After Time-Dependent Propensity Score Matching.
| Characteristic | Patients, No. (%) | P Value | |
|---|---|---|---|
| MILS (n = 104) | Open Surgery (n = 412) | ||
| Age, median (range), y | 62 (35-81) | 60 (37-80) | .10 |
| Sex | |||
| Male | 58 (55.8) | 231 (56.1) | .08 |
| Female | 46 (44.2) | 181 (43.9) | |
| ASA score | |||
| I and II | 70 (67.3) | 355 (86.2) | .16 |
| III and IV | 34 (32.7) | 57 (13.8) | |
| Neoadjuvant CT | 85 (81.7) | 336 (81.6) | .57 |
| Chemotherapy regimen | |||
| Oxaliplatin based | 51 (49.0) | 199 (48.3) | .46 |
| Irinotecan based | 34 (32.7) | 138 (33.5) | |
| Associated biologic therapy | 42 (40.4) | 162 (39.3) | |
| Associated comorbidities | 62 (59.6) | 251 (60.9) | .53 |
| Features of nontumorous parenchyma | |||
| Normal | 56 (53.8) | 213 (51.7) | .35 |
| Steatosis | 31 (29.8) | 129 (31.3) | |
| CALI | 17 (16.3) | 70 (17.0) | |
| Primary tumor location | |||
| Colon | 53 (51.0) | 236 (57.3) | .90 |
| Rectum | 51 (49.0) | 176 (42.7) | |
| Tumor stage | |||
| T1 | 4 (3.8) | 14 (3.4) | .40 |
| T2 | 34 (32.7) | 137 (33.3) | |
| T3 | 51 (49.0) | 200 (48.5) | |
| T4 | 15 (14.4) | 61 (14.8) | |
| Tumor grade | |||
| G1 | 3 (2.9) | 9 (2.2) | .55 |
| G2 | 86 (82.7) | 344 (83.5) | |
| G3 | 15 (14.4) | 59 (14.3) | |
| Nodal status | |||
| N0 | 49 (47.1) | 190 (46.1) | .46 |
| N1 | 43 (41.3) | 173 (42.0) | |
| N2 | 12 (11.5) | 49 (11.9) | |
| No. of liver lesions, median (range) | 2 (1-10) | 2 (1-44) | .38 |
| Nodularity | |||
| Monofocal | 39 (37.5) | 150 (36.4) | .52 |
| Multifocal | 75 (72.1) | 302 (73.3) | |
| Lobe distribution of metastases | |||
| Unilobar | 57 (54.8) | 219 (53.2) | .96 |
| Bilobar | 47 (45.2) | 193 (46.8) | |
| Repeated liver surgery | 19 (18.3) | 75 (18.2) | |
| Previous portal vein embolization or ligation | 6 (5.8) | 27 (6.6) | |
| Extrahepatic disease | 15 (14.4) | 58 (14.1) | |
| Liver metastasis diameter, median (range), cm | 3.4 (0.9-12) | 2.9 (0.5-11) | .41 |
| Fong score, median (range) | 3 (1-5) | 3 (1-5) | .32 |
| CEA level, median (range), ng/mL | 41.8 (3.1-590) | 35.6 (2-276) | .28 |
Abbreviations: ASA, American Society of Anesthesiologists; CALI, chemotherapy-related liver injury; CEA, carcinoembryonic antigen; CT, computed tomography; MILS, minimally invasive liver surgery.
SI conversion factor: To convert CEA to micrograms per liter, multiply by 1.0.